CPT

Dortmund, Germany
Dortmund, Germany
SEARCH FILTERS
Time filter
Source Type

Most patients with hepatitis C virus can be cured by direct-acting antiviral agents (DAAs), but some with the more serious decompensated cirrhosis fail to improve or experience further deterioration even after treatment. Dr. Dunn's team focused on the Rs738409 single nucleotide polymorphism, which is a variation in a single base pair of DNA in the PNPLA3 gene; patients possess one of three genotypes — CC, CG, or GG. The PNPLA3 gene is the most important genetic risk factor for both alcoholic liver disease and nonalcoholic fatty liver disease. The team followed 32 patients with decompensated cirrhosis who had initially achieved sustained virologic response (SVR). They had become essentially virus-free, using interferon-free DAAs. Twelve to 48 weeks after SVR, researchers tracked changes in the Model for End-Stage Liver Disease (MELD) and the Child-Pugh (CPT) scores, measures that assess the severity of chronic liver disease. Following DAA treatment, researchers found that five of the 16 patients with the CG or GG genotypes experienced worsened MELD or CPT scores. In comparison, only one patient with the CC genotype worsened in either score. "These findings suggest screening for the Rs738409 CG and GG genotypes in hepatitis C patients with decompensated cirrhosis can help to identify individuals who are less likely to recover after achieving a 'cure' of their hepatitis C," added Dr. Dunn. Financial support for this study was provided by the Frontiers Pilot and Collaborative Studies Funding Program. Digestive Disease Week (DDW) 2017 is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. More information can be found at www.ddw.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-identifies-genetic-markers-that-predict-which-patients-with-hepatitis-c-and-cirrhosis-will-improve-with-treatment-300454288.html


IRVINE, CA--(Marketwired - May 23, 2017) - Biomerica Inc. ( : BMRA) today announced it will present at the 18th Annual B. Riley institutional investor conference being held May 24-25, 2017 in Santa Monica, CA. Zackary Irani, Chief Executive Officer of Biomerica, will present a business update about the company's InFoods® IBS (Irritable Bowel Syndrome) product. The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The presentation will be available in the Investors section of Biomerica's website at www.biomerica.com, under the News tab. Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing. The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.


LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. blog coverage looks at the headline from New York based Two Harbors Investment Corp. (NYSE: TWO) as the Company announced on May 24, 2017, that it intends to transfer its Commercial Real Estate Assets to Granite Point Mortgage Trust Inc. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Two Harbors Investment's competitors within the REIT - Residential space, Camden Property Trust (NYSE: CPT), announced on May 04, 2017, its operating results for Q1 2017 which ended on March 31, 2017. AWS will be initiating a research report on Camden Property in the coming days. Today, AWS is promoting its blog coverage on TWO; touching on CPT. Get all of our free blog coverage and more by clicking on the link below: http://www.activewallst.com/register/ Two Harbors Investment is a leading hybrid mortgage real estate investment trust (REIT), and a Maryland Corporation. It focuses on investing, financing, and managing residential mortgage-backed securities (RMBS) and related investments. Two Harbors Investment is externally managed and advised by PRCM Advisers LLC, a wholly owned subsidiary of Pine River Capital Management L.P. Two Harbors Investment had started Granite Point, a Maryland corporation, with the intention of expanding the commercial real estate lending business. With the formation of Granite Point, Two Harbors Investment expected it to concentrate on directly originating, investing in, and managing a portfolio of commercial real estate loans and other debt and debt-like instruments. These loans, debt and debt-like instruments would be secured by institutional quality commercial properties which would be managed by experienced owners at lucrative markets across the US. The Pine River Capital Management L.P., which is the parent Company of Two Harbors Investment's external manager, will also externally manage Granit e Point. The transfer of assets will need to be approved by the special committee and 2 members of Two Harbors Investment's Board of Directors. The finalization of the requisite documentation with regards to the transfer will be done on the terms that are acceptable to Two Harbors Investment and the special committee. This will also be done in accordance to the closing conditions of the transaction including clearance from SEC and other market factors. Reasons for the transfer of assets and its result Granite Point has recently filed for an IPO of over $100 million. The Company plans to list its shares at the New York Stock Exchange (NYSE) under the ticker "GMPT". Once the IPO closes, the commercial real estate assets will be immediately transferred to Granite Point. Two Harbors Investment expects to receive shares in Granite Point in exchange for the commercial real estate assets transferred. The amount of capital raised via the IPO as well as the value of the commercial real estate assets transferred to Granite Point will determine the number of shares to be allocated to Two Harbors Investment. This is again subject to the approval of Board of Directors and applicable SEC (US Securities Exchange Commission) laws. Once the shares of Granite Point are allocated to Two Harbors Investment after the IPO, Two Harbors Investment plans to distribute its portion of shares to its shareholders via a special dividend. This will be possible once the lock-up period on the Granite Point shares expires after the completion of the IPO. A committee has been formed by Two Harbors Investment's Board of Directors, which consists of independent directors. This committee has been tasked with the review, negotiation, and approval of the proposed transaction. The committee has also retained the services of Freshfields Bruckhaus Deringer LLP as its legal counsel and Credit Suisse as its financial adviser to assist in the transfer of assets and represent the interests of Two Harbors Investment and its shareholders in the matter. On Thursday, May 25, 2017, the stock closed the trading session at $10.09, slightly slipping 0.10% from its previous closing price of $10.10. A total volume of 2.24 million shares have exchanged hands. Two Harbors Investment's stock price surged 18.71% in the past six months and 18.71% in the previous twelve months. Furthermore, on a year to date basis, the stock rallied 15.71%. The stock is trading at a PE ratio of 6.82 and has a dividend yield of 9.91%. The stock currently has a market cap of $3.53 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. blog coverage looks at the headline from New York based Two Harbors Investment Corp. (NYSE: TWO) as the Company announced on May 24, 2017, that it intends to transfer its Commercial Real Estate Assets to Granite Point Mortgage Trust Inc. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Two Harbors Investment's competitors within the REIT - Residential space, Camden Property Trust (NYSE: CPT), announced on May 04, 2017, its operating results for Q1 2017 which ended on March 31, 2017. AWS will be initiating a research report on Camden Property in the coming days. Today, AWS is promoting its blog coverage on TWO; touching on CPT. Get all of our free blog coverage and more by clicking on the link below: http://www.activewallst.com/register/ Two Harbors Investment is a leading hybrid mortgage real estate investment trust (REIT), and a Maryland Corporation. It focuses on investing, financing, and managing residential mortgage-backed securities (RMBS) and related investments. Two Harbors Investment is externally managed and advised by PRCM Advisers LLC, a wholly owned subsidiary of Pine River Capital Management L.P. Two Harbors Investment had started Granite Point, a Maryland corporation, with the intention of expanding the commercial real estate lending business. With the formation of Granite Point, Two Harbors Investment expected it to concentrate on directly originating, investing in, and managing a portfolio of commercial real estate loans and other debt and debt-like instruments. These loans, debt and debt-like instruments would be secured by institutional quality commercial properties which would be managed by experienced owners at lucrative markets across the US. The Pine River Capital Management L.P., which is the parent Company of Two Harbors Investment's external manager, will also externally manage Granit e Point. The transfer of assets will need to be approved by the special committee and 2 members of Two Harbors Investment's Board of Directors. The finalization of the requisite documentation with regards to the transfer will be done on the terms that are acceptable to Two Harbors Investment and the special committee. This will also be done in accordance to the closing conditions of the transaction including clearance from SEC and other market factors. Reasons for the transfer of assets and its result Granite Point has recently filed for an IPO of over $100 million. The Company plans to list its shares at the New York Stock Exchange (NYSE) under the ticker "GMPT". Once the IPO closes, the commercial real estate assets will be immediately transferred to Granite Point. Two Harbors Investment expects to receive shares in Granite Point in exchange for the commercial real estate assets transferred. The amount of capital raised via the IPO as well as the value of the commercial real estate assets transferred to Granite Point will determine the number of shares to be allocated to Two Harbors Investment. This is again subject to the approval of Board of Directors and applicable SEC (US Securities Exchange Commission) laws. Once the shares of Granite Point are allocated to Two Harbors Investment after the IPO, Two Harbors Investment plans to distribute its portion of shares to its shareholders via a special dividend. This will be possible once the lock-up period on the Granite Point shares expires after the completion of the IPO. A committee has been formed by Two Harbors Investment's Board of Directors, which consists of independent directors. This committee has been tasked with the review, negotiation, and approval of the proposed transaction. The committee has also retained the services of Freshfields Bruckhaus Deringer LLP as its legal counsel and Credit Suisse as its financial adviser to assist in the transfer of assets and represent the interests of Two Harbors Investment and its shareholders in the matter. On Thursday, May 25, 2017, the stock closed the trading session at $10.09, slightly slipping 0.10% from its previous closing price of $10.10. A total volume of 2.24 million shares have exchanged hands. Two Harbors Investment's stock price surged 18.71% in the past six months and 18.71% in the previous twelve months. Furthermore, on a year to date basis, the stock rallied 15.71%. The stock is trading at a PE ratio of 6.82 and has a dividend yield of 9.91%. The stock currently has a market cap of $3.53 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. blog coverage looks at the headline from New York based Two Harbors Investment Corp. (NYSE: TWO) as the Company announced on May 24, 2017, that it intends to transfer its Commercial Real Estate Assets to Granite Point Mortgage Trust Inc. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of Two Harbors Investment's competitors within the REIT - Residential space, Camden Property Trust (NYSE: CPT), announced on May 04, 2017, its operating results for Q1 2017 which ended on March 31, 2017. AWS will be initiating a research report on Camden Property in the coming days. Today, AWS is promoting its blog coverage on TWO; touching on CPT. Get all of our free blog coverage and more by clicking on the link below: http://www.activewallst.com/register/ Two Harbors Investment is a leading hybrid mortgage real estate investment trust (REIT), and a Maryland Corporation. It focuses on investing, financing, and managing residential mortgage-backed securities (RMBS) and related investments. Two Harbors Investment is externally managed and advised by PRCM Advisers LLC, a wholly owned subsidiary of Pine River Capital Management L.P. Two Harbors Investment had started Granite Point, a Maryland corporation, with the intention of expanding the commercial real estate lending business. With the formation of Granite Point, Two Harbors Investment expected it to concentrate on directly originating, investing in, and managing a portfolio of commercial real estate loans and other debt and debt-like instruments. These loans, debt and debt-like instruments would be secured by institutional quality commercial properties which would be managed by experienced owners at lucrative markets across the US. The Pine River Capital Management L.P., which is the parent Company of Two Harbors Investment's external manager, will also externally manage Granit e Point. The transfer of assets will need to be approved by the special committee and 2 members of Two Harbors Investment's Board of Directors. The finalization of the requisite documentation with regards to the transfer will be done on the terms that are acceptable to Two Harbors Investment and the special committee. This will also be done in accordance to the closing conditions of the transaction including clearance from SEC and other market factors. Reasons for the transfer of assets and its result Granite Point has recently filed for an IPO of over $100 million. The Company plans to list its shares at the New York Stock Exchange (NYSE) under the ticker "GMPT". Once the IPO closes, the commercial real estate assets will be immediately transferred to Granite Point. Two Harbors Investment expects to receive shares in Granite Point in exchange for the commercial real estate assets transferred. The amount of capital raised via the IPO as well as the value of the commercial real estate assets transferred to Granite Point will determine the number of shares to be allocated to Two Harbors Investment. This is again subject to the approval of Board of Directors and applicable SEC (US Securities Exchange Commission) laws. Once the shares of Granite Point are allocated to Two Harbors Investment after the IPO, Two Harbors Investment plans to distribute its portion of shares to its shareholders via a special dividend. This will be possible once the lock-up period on the Granite Point shares expires after the completion of the IPO. A committee has been formed by Two Harbors Investment's Board of Directors, which consists of independent directors. This committee has been tasked with the review, negotiation, and approval of the proposed transaction. The committee has also retained the services of Freshfields Bruckhaus Deringer LLP as its legal counsel and Credit Suisse as its financial adviser to assist in the transfer of assets and represent the interests of Two Harbors Investment and its shareholders in the matter. On Thursday, May 25, 2017, the stock closed the trading session at $10.09, slightly slipping 0.10% from its previous closing price of $10.10. A total volume of 2.24 million shares have exchanged hands. Two Harbors Investment's stock price surged 18.71% in the past six months and 18.71% in the previous twelve months. Furthermore, on a year to date basis, the stock rallied 15.71%. The stock is trading at a PE ratio of 6.82 and has a dividend yield of 9.91%. The stock currently has a market cap of $3.53 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | May 23, 2017
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global motorcycle supercharger market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline. Siddharth Jaiswal, a lead analyst from Technavio, specializing in research on automotive components sector, says, “The high-volume sales of performance and sports bikes in the developed economies of Europe, the US, Canada, and Japan drive the market growth with their offerings of supercharged motorcycles. The increase in the number of regulations on high fuel economy and emission limits will also fuel the market growth for superchargers.” One of the biggest advantages that the supercharger enjoys over the turbocharger is the reduction in lag. The turbocharger is primarily driven by exhaust gases, wherein the turbocharger's turbine rolls up before it begins to turn the compressor's impeller. This results in lag time that is defined by the time needed for the turbine to reach to the full throttle from an intermediate rotational speed state. Looking for more information on this market? Request a free sample report Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. The top three emerging trends driving the global motorcycle supercharger market according to Technavio research analysts are: The global motorcycle industry is evolving rapidly with the increase in innovations and improvements in the industry. The growing popularity of racing and performance motorcycles has progressively made way for the integration of performance boosting systems in motorcycles. “The integration of forced induction systems in motorcycles result in significant improvements in the power output of the motorcycle and help in reducing carbon emission levels. Some of the leading motorcycle manufacturers have leveraged their expertise with advanced forced induction systems to manufacture powerful motorcycles,” according to Siddharth. The coming-of-age automotive technology has resulted in the development of technologically advanced systems and components. The industry shift toward electrification, which involves the increasing use of an electronic content per vehicle or motorcycle, has resulted in a significantly higher efficiency of the systems with more precision and accuracy. There have been several advances in the field of supercharging technology and other fields of forced induction systems. One such prominent development in the field of superchargers is the advent of Controlled Power Technologies (CPT) in electric superchargers. The global automotive industry is moving toward engine downsizing with the advent of stringent norms and regulations for higher fuel efficiency and reduced carbon emissions. The industry shift has resulted in significantly higher fuel economy with minimum power difference, owing to the integration of forced induction technologies in the engine. The automotive industry is witnessing an integration of multistage supercharging, which significantly increases the drivability or rideability and results in torque enhancement. OEMs are developing advanced two-stage or three-stage supercharging, which is expected to be a major trend in the global automotive supercharger market during the forecast period. The key vendors are as follows: Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like automotive electronics, automotive manufacturing, and powertrain. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently. Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at media@technavio.com.


News Article | May 9, 2017
Site: www.prweb.com

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the appointment of Andy Turner as Country Director of Australia and New Zealand to support continued growth and investment of OrthAlign technologies in that region of the world. He will be based in Sydney. Andy has over twenty years experience in the orthopaedic industry, in both the sales and marketing functions. His career began in Europe with DePuy, followed by a move to Biomet, where he was responsible for launching the Vanguard knee system across Europe. Andy moved to Australia in 2008 and has held senior management and executive positions for Smith & Nephew and ZimmerBiomet, where he was responsible for marketing, sales, and product management of the orthopedic portfolios. During his career, he has successfully managed some of the largest global orthopedic brands, namely, Legion, CPCS, Polar, NexGen, Oxford, and CPT, respectively. Andy’s strong commercial acumen and sales drive has resulted in meeting corporate objectives and financial targets at every stage of his career. He holds an Honors Degree in Management with a Major in Physiology from Hallam University, Sheffield, UK. “The addition of Andy as a local leader for OrthAlign in Australia and New Zealand is just one of many major investments that we are making in those very important markets. KneeAlign® has already established itself as one of the leading orthopaedic technologies in ANZ, but OrthAlign technology is just scratching the surface," said James Young Kim, OrthAlign’s Vice President and General Manager of International. "Andy's local presence will greatly enhance our continued efforts in customer expansion, growth in our portfolio of products, and focus in providing world class customer service to our surgeons, hospitals, and surgery centers. With 65,000 knee and 45,000 hip arthroplasties completed in Australia and New Zealand in 2016, we are excited about the growth opportunities that are before us.” OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit http://www.orthalign.com. “ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”


News Article | May 11, 2017
Site: www.prlog.org

-- Although Medicare began paying for chronic care management (CCM) services in 2016, the Centers for Medicare and Medicaid Services (CMS) reports that many practices are not taking advantage of the new coverage, even after more than a year. And if you're not billing this service for those who are likely your sickest patients, you're losing out on significant reimbursement.When your practitioner provides CCM services, he manages a patient's medical, functional and psychosocial needs. This includes spending at least 20 minutes each month on things like medication management and coordinating other therapeutic services. Your office also becomes the point of contact for patients and their caregivers not only through telephone access, but also via secure messaging, Internet or other non-face-to-face consultation. Your office has to be able to provide these services any time of day or night to qualify for CCM reimbursement (either via your in-house staff or a third party).If your clinician(s)documents the service correctly and you properly apply CCM code 99490, Medicare will reimburse your office for this time at a rate of roughly $42 for each patient per 30-day period in 2017. Although this doesn't sound like much, it can quickly add up. For instance, if you provide CCM services to 100 Medicare patients each month, and code these services based on CCM guidelines, you could bring in $42,000 extra per year. Also, you can bill for other services in addition to CCM, which means this reimbursement is on top of what you normally receive.For example, an elderly patient with multiple illnesses and dementia bound for a nursing home can have as many as 10 different doctors — half of whom may be prescribing medications. Patients and their families find dealing with so many different specialists bewildering and stressful. At the same time, CMS believes that its payers spend more than two-thirds of Medicare dollars on these patients.CCM is meant to address this situation by helping to:• Manage these different providers' care.• Ensure all medication prescribed makes sense for the patient when• taken together.• Reduce the expense of uncoordinated services by paying one primary care physician to serve as the point of contact for all the patient's care.For 2017, CMS will also pay for complex chronic care management with codes 99487 and +99489. You can find out more about coding and billing for this service in a previous blog ( https://codingleader.com/ blogs/compliancepop/ ccm-2017 ) and in Coding Leader's Chronic Care Management Coding 2017 Expert Report ( https://codingleader.com/ products/chronic- care-management... ).So if you've chalked up CCM as more trouble than it's worth, you might want to reconsider what these services could mean for your practice. In many cases, you may find that you're already performing this level of service, and you should be reimbursed accordingly.• If you're providing at least 20 minutes of chronic care management services, you should be reporting them with 99490.• Patients and their families prefer to have a single point of contact for their care, and this could be a significant income for your practice.• CCM can improve patient care and safety by coordinating the efforts of multiple providers and reducing duplicated or contradictory services.For more strategies for effectively addressing chronic care management related challenges, check out Coding Leader's online training session — Chronic Care Management 2017 CPT Coding Update (https://codingleader.com/products/2017-ccm-update). And you can view all upcoming live online training sessions at https://codingleader.com/pages/online-training-calendar.


Two Studies Presented at DDW 2017 Showed Clinically Meaningful Reduction in Symptoms and Withdrawal or Reduction in Proton Pump Inhibitor Use by Two-Thirds of Patients Following Treatment with MUSE™ System Separate Presentation Supports HOF Criteria as a Potential Endoscopic Selection Criteria to Predict Amount of Reflux and Improve Treatment Outcomes OMER, ISRAEL--(Marketwired - May 9, 2017) - Medigus Ltd. ( : MDGS) ( : MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced results from three clinical studies involving the company's MUSE™ System, a minimally invasive solution for gastroesophageal reflux disease (GERD). The data were presented in three posters at Digestive Disease Week® (DDW), taking place in Chicago from May 6-9, 2017. The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication -- the procedure is intended to treat the anatomical cause of gastroesophageal reflux disease (GERD), commonly known as acid reflux. Giorgia Mazzoleni, fellow at the San Raffaele Scientific Institute at the San Raffaele Hospital in Milan, Italy, presented a poster entitled, "Transoral Anterior Fundoplication (TAF) with Medigus Ultrasound Surgical Endostapler (MUSE™) for the Treatment of Gastroesophageal Reflux Disease (GERD); 6-Month Results from a Single-Center Prospective Study," which enrolled 24 GERD patients to assess the six-month safety and efficacy of TAF with MUSE. GERD quality of life questionnaires (HRQL) improved from a baseline of 43 to 18 six months after TAF with MUSE (p < 0.003). The study also highlighted an improvement in Reflux Symptom Index (RSI), from 21 to 10 (p < 0.009). A 79% reduction or withdrawal in PPI therapy was observed six-months after treatment, with 50% of patients stopping PPI use, 28.6% of patients halving PPI use, and 21.4% remaining on the same dose prior to treatment with TAF with MUSE. Dr. Ali Lankarani, board member of the Advanced Therapeutic Endoscopy Center (ATEC) at the Broland-Groover Clinic in Jacksonville, FL, presented a poster titled, "Interim Results From A Multi-Center Post-Marketing Surveillance Registry Study for Endoscopic Anterior Fundoplication," reported data from an ongoing post-market registry study of 68 GERD patients who underwent Endoscopic Anterior Fundoplication (EAF) in 13 international centers. GERD-HRQL improved from 24.0 to 6.0 following treatment with MUSE (CI, 13.4 - 20.8, p < 0.00001), demonstrating patients experienced a clinically meaningful reduction in GERD-related symptoms. In addition, baseline patient satisfaction was reported at 0%, but improved to 70% (26/37) at 6 months and 90% (9/10) at 1 year. Of note, 76% (28/37; p < 0.00001) of patients have eliminated or reduced their use of proton pump inhibitors (PPI), with 96% of patients that responded favorably to treatment with the MUSE System stopping daily PPI therapy. Dr. Lankarani remarked, "These interim results, in conjunction with the data from the single-center study presented by Mazzoleni, highlight how the MUSE System can be a revolutionary, minimally-invasive treatment option for patients with GERD who are unsatisfied with PPI therapeutics and hesitant to pursue surgical intervention. In addition to the impressive findings, in another study we were able to access the value of the HOF criteria over the Hill classification, which we believe will play a pivotal role alongside the MUSE System in improving overall treatment outcomes in GERD." In addition, Dr. Lankarani presented a second poster, entitled, "Endoscopic Predictors of Decreased Reflux After Endoscopic Anterior Fundoplasty," which evaluated the HOF criteria as an endoscopic grading system of gastroesophageal junction (GEJ) geometry, as well as selection criteria to guide treatment decisions and predict treatment outcomes. Currently, Hill classification is the most commonly used criteria for antireflux procedures, however it has limited utility and still results in one-third of EAF-treated patients to continue experiencing reflux. HOF criteria categorizes GEJ geometry based on measurement of axial length of hiatal hernia (H), hiatus opening dimension (O) and flap valve size (F), with H and O openings less than 1cm considered normal (N) and 1cm or larger categorized as abnormal (A). GEJ is categorized as AAA if all three HOF landmarks are abnormal, NAA if one HOF landmark is normal and two are abnormal, and NNN if all three HOF landmarks are normal. Using the HOF criteria, the researchers identified and successfully treated 18 GERD patients, with Total Present of Time spent in Reflux (TPTR) showing a reduction in all patients with NAA configuration, and 75% and 71% TPTR reduction in individuals that had a 1 and 2 cm hiatal hernia, respectively. Average TPTR improvement was 53% for the NAA configuration patients, while average TPTR improvement in patients with 1 and 2 cm hiatal hernia was 56% and 46%, respectively. Chris Rowland, Chief Executive Officer of Medigus, commented, "As the developers of a completely new, minimally invasive solution for the treatment of GERD, we are extremely motivated by data presented this year at DDW. We are pleased with the results reported from the single center study, and look forward to continuing the ongoing post-market multi-center study, which have shown promising reductions in PPI reliance, as well as increases in patient quality of life and satisfaction. These studies continue to support the use of our MUSE System, which can reduce the need for pharmaceuticals and invasive surgical procedures." To learn more about MUSE, visit: www.medigus.com Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world -- it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.RefluxHelp.com. This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus' expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the Company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.


Houston, Texas headquartered Camden Property Trust's stock edged 0.48% lower, to close the day at $81.70. The stock recorded a trading volume of 480,542 shares. Camden Property Trust's shares have advanced 0.31% in the previous three months and 4.03% in the past one year. The Company's shares are trading 0.62% and 1.56% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which invests in the real estate markets of the US, are trading at a PE ratio of 17.07. Additionally, the stock has a Relative Strength Index (RSI) of 50.63. CPT complete research report is just a click away and free at: On Thursday, shares in US-based Independence Realty Trust Inc. ended the session 0.55% lower at $9.02, with a total volume of 293,050 shares traded. Independence Realty Trust's shares have gained 17.14% in the past one year. Shares of the Company, which makes investments in apartment properties to create its portfolio, are trading at a PE ratio of 80.54. The stock is trading 1.92% below its 50-day moving average and 0.90% below its 200-day moving average. Moreover, the Company's shares have an RSI of 44.22. The complimentary report on IRT can be downloaded at: On Thursday, shares in Vero Beach, Florida-based ARMOUR Residential REIT Inc. recorded a trading volume of 257,724 shares. The stock ended the day 1.04% lower at $24.82. ARMOUR Residential REIT Inc.'s stock has advanced 5.39% in the last one month and 14.06% in the previous three months. Furthermore, the stock has gained 21.19% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 7.15% and 10.92%, respectively. Furthermore, shares of ARMOUR Residential REIT, which invests in residential mortgage backed securities in the US, are trading at a PE ratio of 3.36. The stock has an RSI of 61.03. Sign up for your complimentary research report on ARR at: Memphis, Tennessee-based EdR's stock finished Thursday's session 1.03% lower at $37.54, with a total volume of 440,201 shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 4.90% and 8.56%, respectively. Shares of EdR, which develops, acquires, owns, and manages collegiate housing communities located near university campuses, are trading at a PE ratio of 84.55. The stock has an RSI of 39.05. On May 02nd, 2017, research firm Canaccord Genuity reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $43 a share to $42 a share. Get free access to your research report on EDR at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


BILLERICA, Mass--(BUSINESS WIRE)--SRS Medical, Inc., announced today the publication of additional clinical efficacy data on the use of its Spanner® Temporary Prostate Stent. The Canadian Journal of Urology published the clinical results of 214 stent placements in male patients with symptoms of benign prostatic hyperplasia (BPH). The findings affirm that the fully-internal device effectively restores natural urination with a low infection rate and high patient quality of life. Data showed that The Spanner allowed patients to maintain natural urination, reducing the measure of urine remaining in the bladder after void by 81%. Each device was implanted for 30 days, with six of 214 placements resulting in a symptomatic urinary tract infection (0.93 infections per 1,000 stent days). In comparison to published data on chronically catheterized male patients, Spanner patients demonstrated a greater than 75% reduction in symptomatic infection rate as compared to indwelling catheter patients. “Our patients are having remarkable clinical success with The Spanner,” said Richard Roach, MD, author of the study and partner at Advanced Urology Institute of Oxford, FL. “Men who transition to the stent are often able to break the cycle of urinary tract infections caused by catheter use. In addition, eliminating the catheter has a profound impact on the patient’s medical condition and overall health.” Unlike urinary catheters, The Spanner does not require external components to enable bladder drainage. Instead, a completely internal design permits The Spanner to stent the prostate while maintaining urinary continence. The device preserves natural voiding habits, often with no device awareness, and reduces exposure to potentially harmful bacteria in the surrounding environment. “The Spanner Stent is a significantly better clinical solution than a urinary catheter for most male retention patients,” said Lee Brody, CEO of SRS Medical. “The stent offers a higher quality of life, with lower complication rates, including the elimination of most urinary tract infections caused by catheter use. The high efficacy reported in the recent peer-reviewed literature is consistent with the clinical successes that our urologist clients and their patients are experiencing around the world.” The Spanner Temporary Prostatic Stent is CE marked and an FDA-approved Class III medical device intended to maintain urine flow and allow for voluntary urination in certain male patients experiencing lower urinary tract symptoms (LUTS). The device consists of two anchors and a silicone tube that reduces resistance in the bladder neck and prostatic urethra without stenting the external sphincter. The Spanner is placed blindly without anesthesia, in a procedure similar to the placement of a Foley catheter. The Spanner is reimbursed under CPT Code 53855. SRS Medical is dedicated to improving the health and well-being of men experiencing LUTS. The company, based in Billerica, Mass., does this by delivering innovative, cost-effective tools to urologists, enabling them to better diagnose and treat these patients. For more information about SRS Medical: www.srsmedical.com.

Loading CPT collaborators
Loading CPT collaborators